Translational research in inflammatory bowel disease

Mount Sinai Journal of Medicine

Volumn 73, Issue 8, 2006, Pages 1067-1073

  Abreu, Maria T ^a,b   Sparrow, Miles P ^b  

^a Inflammatory Bowel Disease Center   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immunity; Biological therapies; Crohn's disease; Inflammatory bowel disease; Innate immunity; Ulcerative colitis

Indexed keywords

ANTIGEN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR9; CIPROFLOXACIN; FONTOLIZUMAB; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12P40; INTERLEUKIN 23; METRONIDAZOLE; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; PROBIOTIC AGENT; TOLL LIKE RECEPTOR; VISILIZUMAB;

ANTIINFLAMMATORY ACTIVITY; ANUS FISTULA; ARTICLE; BACTERIUM; CLINICAL TRIAL; COLON CROHN DISEASE; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DENDRITIC CELL; DISEASE CLASSIFICATION; ENTERITIS; GENETIC PREDISPOSITION; HUMAN; ILEITIS; MEDICAL RESEARCH; MOLECULAR INTERACTION; MONOTHERAPY; MUCOSAL IMMUNITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN FUNCTION; ULCERATIVE COLITIS;

CYTOKINES; EPITHELIUM; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; T-LYMPHOCYTES;

EID: 33847707417     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003; 124(2):521-536.
2. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411(6837):599-603.
3. Watanabe T, Kitani A, Murray PJ, et al. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004; 5(8):800-808.
4. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123(3):679-688.
5. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004; 36(5):471-475.
6. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006; 52(2):171-181.
7. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004; 99(12):2376-2384.
8. Sonnenburg JL, Angenent LT, Gordon JI. Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat Immunol 2004; 5(6):569-573.
9. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52(1):65-70.
10. Yen D, Cheung J,. Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116(5):1310-1316.
11. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3(2):133-146.
12. Davidson NJ, Hudak SA, Lesley RE, et al. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998; 161(6):3143-3149.
13. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351(20):2069-2079.
14. van Assche G, Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis 2002; 8(4):291-300.
15. Abbas A, Lichtman A, Pober J. Cellular and molecular immunology. 4th ed. W.B. Saunders; 2000. Innate and adaptive immunity. Fig. 1.1, p. 4.
16. Abreu MT, Arditi M. Innate immunity and toll-like receptors: clinical implications of basic science research. J Pediatr 2004; 144(4):421-429.
17. Kobayashi M, Kweon MN, Kuwata H, et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 2003; 111(9):1297-1308.
18. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272(5258):60-66.
19. de Baey A, Mende I, Baretton G, et al. A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Immunol 2003; 170(10):5089-5094.
20. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337(15):1029-1035.
21. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340(18):1398-1405.
22. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317):1541-1549.
23. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23):2462-2476.
24. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129(3):807-818.
25. Sandborn WJ, Hanauer S, Loftus EV, Jr., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99(10):1984-1989.
26. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10(4):333-338.
27. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130(2):323-333; quiz 591.
28. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon {gamma} antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006; 55(8):1131-1137.
29. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99(8):2712-2719.
30. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353(18):1912-1925.
31. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348(1):24-32.
32. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352(24):2499-2507.
33. Van Assche G, van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353(4):362-368.
34. Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002. 8(1):10-15.
35. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 1998; 12(1):53-56.
36. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32(9):1071-1075.
37. Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003; 18(11-12):1113-1120.
38. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7(4):301-305.
39. Mantzaris GJ, Archavlis E, Christoforidis P, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997; 92(3):454-456.
40. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121(3):580-591.
41. Pathmakanthan S, Li CK, Cowie J, et al. Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 2004; 19(2):166-173.
42. Shiba T, Aiba Y, Ishikawa H, et al. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol 2003; 47(6):371-378.
43. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124(5):1202-1209.
44. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119(2):305-309.
45. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53(1):108-114.
46. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005; 11(9):833-839.
47. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000; 45(7):1462-1464.
48. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15(6):697-698.